Search for a trial

A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC
and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and
Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in
Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended
for Autologous Stem Cell Transplant as Initial Therapy

This study has been transitioned to CTIS with ID 2023-503442-30-00 check the CTIS register for the current data. The purpose of this study is to compare the efficacy of teclistamab and talquetamab both in combination with daratumumab and…

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE* FL-1)

This study has been transitioned to CTIS with ID 2023-505628-67-00 check the CTIS register for the current data. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult…

A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

This study has been transitioned to CTIS with ID 2024-518304-53-00 check the CTIS register for the current data. The primary objective of the study is to compare the PFS of SPd versus EloPd in patients with MM who have received 1 to 4 prior anti-MM…

A Phase 3, 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome.

This study has been transitioned to CTIS with ID 2023-510110-36-00 check the CTIS register for the current data. Primary objective: To evaluate the efficacy of mepolizumab SC given every 4 weeks in participants aged 6 to 17 years with HESSecondary…

A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with
advanced solid malignant tumors

DOSE ESCALATION PHASE: PART A: Primary Objectives: • To assess the safety and tolerability of KBA1412 when given as monotherapy. • To determine the maximum tolerated dose (MTD) and/or Recommended Phase II dose (RP2D) of KBA1412 when given as…

A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies

This study has been transitioned to CTIS with ID 2023-510144-20-00 check the CTIS register for the current data. The current study is designed to evaluate the preliminary safety and efficacy of BLU-263 in patients with AdvSM, including in those with…

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

This study has been transitioned to CTIS with ID 2023-509750-58-00 check the CTIS register for the current data. In this study, we look at how safe the new medicinal product rusfertide is for the treatment of Polycythemia vera. And how well it works…

A Four-Part, Open Label, Randomized, Parallel Assignment Study to Evaluate the Pharmacodynamics of Nirogacestat on B-Cell Maturation Antigen (BCMA)

Part 1In Part 1 of the study, no study compound will be administered, but a bone marrow aspiration and a blood sample will be taken to evaluate an assay that will be used for Part 2 and Part 3 of the study. Because no nirogacestat is given, we can…

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide

This study has been transitioned to CTIS with ID 2023-503444-13-00 check the CTIS register for the current data. The primary objective of this study is to compare the efficacy of teclistamab monotherapy (Arm A) with that of an investigator*s choice…

A Phase 3 Randomized Study Comparing Talquetamab in Combination with Daratumumab (SC) and Pomalidomide (Tal-DP) or Talquetamab (SC) in combination with Daratumumab SC (Tal-D) versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

This study has been transitioned to CTIS with ID 2023-503467-41-00 check the CTIS register for the current data. The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and…

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

This study has been transitioned to CTIS with ID 2023-503679-12-00 check the CTIS register for the current data. Part 1 (Dose Escalation) - to identify the recommended Phase 2 dose(s) and schedule(s) to be safe for JNJ-79635322. Part 2 (Dose…